Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementation and evaluation of a community walking blood bank for haemorrhagic shock when banked blood is unavailable: protocol for a mixed-methods, effectiveness-implementation study - phase 2 of the Local Initiative for emergency blood (LIFE-Blood) study.

BMJ open·2026
Same author

The need for dried plasma-Still a national issue: Where are we and recommendations.

Transfusion·2026
Same author

Factors associated with aggregate formation in cold-stored platelets.

Vox sanguinis·2026
Same author

Next generation spray-dried on-demand plasma: A multicenter, randomized, dose-escalation, first-in-human safety study.

Transfusion·2026
Same author

Spray-dried plasma is comparable to conventional plasma products used in the resuscitation of major hemorrhage: In vitro characterization.

Transfusion·2026
Same author

A novel intronic variant ABO*AW allele resulting in weak A expression.

Transfusion·2026

Related Experiment Video

Updated: Sep 11, 2025

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

13.7K

Chilling controversy: cold-stored platelets for prophylactic transfusions.

Moritz Stolla1,2,3,4, Andrew P Cap5, Philip C Spinella6

  • 1Bloodworks Northwest Research Institute, Bloodworks Northwest, Seattle, WA.

Blood
|August 11, 2025
PubMed
Summary

The FDA now allows 14-day cold-stored platelets for bleeding patients, increasing availability in hospitals. Their use for prophylaxis in thrombocytopenia requires further study, despite recent room temperature-stored platelet trial data.

More Related Videos

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

28.9K
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.0K

Related Experiment Videos

Last Updated: Sep 11, 2025

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

13.7K
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

28.9K
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.0K

Area of Science:

  • Hematology
  • Transfusion Medicine
  • Clinical Policy

Background:

  • FDA approval of 14-day cold-stored platelets marks a policy reversal from their 1970s discontinuation due to short circulation.
  • This change enhances platelet availability in US hospitals, particularly in trauma centers and rural areas.

Purpose of the Study:

  • To review the history and rationale behind cold-stored platelet discontinuation and recent re-licensure.
  • To analyze recent clinical trial data on room temperature-stored platelets and their transfusion intervals.
  • To critically evaluate the role of platelet count as a transfusion trigger.

Main Methods:

  • Review of historical data on cold-stored platelets.
  • Analysis of recent clinical trial findings for room temperature-stored platelets.
  • Examination of the correlation between platelet counts and bleeding events.

Main Results:

  • Cold-stored platelets are now available for bleeding patients, improving accessibility.
  • Recent trials show similar transfusion intervals for room temperature-stored platelets as potentially achievable with cold-stored platelets.
  • The direct correlation between morning platelet counts and bleeding risk is questionable, suggesting multifactorial causes.

Conclusions:

  • While using cold-stored platelets for prophylaxis may seem unconventional, expanded indications show promise.
  • Further research is needed to determine the efficacy of cold-stored platelets for prophylactic transfusions in hypoproliferative thrombocytopenia.
  • Transfusion strategies may need to consider factors beyond just platelet count, including red blood cells, coagulation factors, and vascular health.